Gossamer Bio's seralutinib shows promise in PAH Phase 2 trials, but Phase 3 success is vital amidst competition. Click to ...

There’s a very specific thrill in swapping out your clunky old rucksack for a sleek, streamlined fastpack that seems to disappear once you put it on, and that’s exactly what Gossamer Gear ...

SAN DIEGO, May 07, 2025--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for ...

Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial ...